285 related articles for article (PubMed ID: 16714186)
41. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
Chu DW; Hwang SJ; Lim FS; Oh HM; Thongcharoen P; Yang PC; Bock HL; Dramé M; Gillard P; Hutagalung Y; Tang H; Teoh YL; Ballou RW;
Vaccine; 2009 Dec; 27(52):7428-35. PubMed ID: 19683087
[TBL] [Abstract][Full Text] [Related]
42. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
43. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
Godeaux O; Izurieta P; Madariaga M; Dramé M; Li P; Vaughn DW
Vaccine; 2015 Apr; 33(18):2189-95. PubMed ID: 25090645
[TBL] [Abstract][Full Text] [Related]
45. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
[TBL] [Abstract][Full Text] [Related]
46. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
47. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
[TBL] [Abstract][Full Text] [Related]
48. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs.
De Vleeschauwer AR; Baras B; Kyriakis CS; Jacob V; Planty C; Giannini SL; Mossman S; Van Reeth K
Vaccine; 2012 Aug; 30(37):5557-63. PubMed ID: 22727727
[TBL] [Abstract][Full Text] [Related]
50. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
Jones T
Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
[TBL] [Abstract][Full Text] [Related]
51. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
52. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.
Saitoh A; Nagai A; Tenjinbaru K; Li P; Vaughn DW; Roman F; Kato T
Hum Vaccin Immunother; 2012 Jun; 8(6):749-58. PubMed ID: 22495117
[TBL] [Abstract][Full Text] [Related]
53. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
54. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
Layton RC; Gigliotti A; Armijo P; Myers L; Knight J; Donart N; Pyles J; Vaughan S; Plourde J; Fomukong N; Harrod KS; Gao P; Koster F
PLoS One; 2011; 6(6):e20641. PubMed ID: 21687736
[TBL] [Abstract][Full Text] [Related]
55. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.
Leroux-Roels I; Bernhard R; Gérard P; Dramé M; Hanon E; Leroux-Roels G
PLoS One; 2008 Feb; 3(2):e1665. PubMed ID: 18301743
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
[TBL] [Abstract][Full Text] [Related]
57. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
58. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
59. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.
Ledgerwood JE; Wei CJ; Hu Z; Gordon IJ; Enama ME; Hendel CS; McTamney PM; Pearce MB; Yassine HM; Boyington JC; Bailer R; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
Lancet Infect Dis; 2011 Dec; 11(12):916-24. PubMed ID: 21975270
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.
Keitel WA; Campbell JD; Treanor JJ; Walter EB; Patel SM; He F; Noah DL; Hill H
J Infect Dis; 2008 Nov; 198(9):1309-16. PubMed ID: 18808338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
